CN106619876A - Pharmaceutical composition for treating anorexia - Google Patents

Pharmaceutical composition for treating anorexia Download PDF

Info

Publication number
CN106619876A
CN106619876A CN201611252700.5A CN201611252700A CN106619876A CN 106619876 A CN106619876 A CN 106619876A CN 201611252700 A CN201611252700 A CN 201611252700A CN 106619876 A CN106619876 A CN 106619876A
Authority
CN
China
Prior art keywords
parts
pharmaceutical composition
mixed
powder
apositia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201611252700.5A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou Palm Network Technology Co Ltd
Original Assignee
Zhengzhou Palm Network Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Palm Network Technology Co Ltd filed Critical Zhengzhou Palm Network Technology Co Ltd
Priority to CN201611252700.5A priority Critical patent/CN106619876A/en
Publication of CN106619876A publication Critical patent/CN106619876A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention discloses pharmaceutical composition for treating anorexia. The composition is prepared from raw materials in parts by weight as follows: 5-10 parts of melanterite, 1-5 parts of pilocarpine, 0.1-1 part of decavitamin, 1-3 parts of hawthorn fruits, 5-20 parts of a bromisovale and procaine injection, 1-5 parts of algin, 2-8 parts of cattle bone meal, 1-3 parts of isosilybin, 2-5 parts of honey, 2-5 parts of soy isoflavone, 3-10 parts of olive oil, 2-5 parts of methylephedrine and 0.5-1 part of maslinic acid. The raw materials are compounded to have a synergistic effect, the pharmaceutical composition for treating the anorexia has the curative effects of invigorating the spleen, replenishing qi, resolving dampness, warming the stomach, tonifying qi and nourishing bodies, can effectively the anorexia without recurrence after the medicine composition is stopped, has small side effects, cannot cause complications, has a better use effect and protects the health of people.

Description

A kind of pharmaceutical composition for treating apositia
Technical field
The present invention relates to a kind of pharmaceutical composition, specifically a kind of pharmaceutical composition for treating apositia.
Background technology
Apositia is the symptom based on longer-term anorexia or anorexia.It is a kind of symptom, not a kind of independent Disease.Main clinical manifestation has a gastrointestinal symptoms such as chilly, constipation, gasteremphraxis, Nausea and vomiting, belch, fatigue and weak, dizziness, Faint, nervous, palpitaition, shortness of breath, pectoralgia, feel dizzy, menopause (non-oral contraceptive), infertile, sleep quality declines, early awakening Deng.These symptoms not only reflect gastral feature or organic disease, and when often occurring in the disease of other systems, especially When being more common in central nervous system disease or phrenoblabia and multi-infection disease.
The medicine of diversified treatment apositia is occurred in that in the market, and effect is also very different, although wherein Some have a kind of effect, but side effect is larger, and can produce serious complication, easily recur after drug withdrawal, using effect It is really poor, the serious harm health of people.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for treating apositia, to solve above-mentioned background technology in carry The problem for going out.
For achieving the above object, the present invention provides following technical scheme：
A kind of pharmaceutical composition for treating apositia, including the raw material of following parts by weight：Melanterite 5-10 parts, Pilocarpus jaborandi Alkali 1-5 parts, B B-complex 0.1-1 parts, hawthorn 1-3 parts, bromisoval Procaine injection 5-20 parts, seaweeds 1-5 parts, ox Bone meal 2-8 parts, Isosilybin 1-3 parts, honey 2-5 parts, isoflavones 2-5 parts, olive oil 3-10 parts, methylephedrine 2- 5 parts, crataegolic acid 0.5-1 parts.
As further scheme of the invention：Including the raw material of following parts by weight：Melanterite 6-9 parts, pilocarpinum 2- 3.5 parts, B B-complex 0.4-0.8 parts, hawthorn 1.5-2 parts, bromisoval Procaine injection 10-18 parts, seaweeds 1.5- 3.5 parts, bovine bone powder 3-5 parts, Isosilybin 1.5-2 parts, honey 3-4 parts, isoflavones 3-4.5 parts, olive oil 5-8 parts, Methylephedrine 3-4 parts, crataegolic acid 0.6-0.8 parts.
As further scheme of the invention：Including the raw material of following parts by weight：8 parts of melanterite, pilocarpinum 3 It is part, 0.6 part of B B-complex, 1.8 parts of hawthorn, 15 parts of bromisoval Procaine injection, 2 parts of seaweeds, 4 parts of bovine bone powder, different 1.7 parts of legalon, 3.5 parts of honey, 4 parts of isoflavones, 7 parts of olive oil, 3.5 parts of methylephedrine, 0.7 part of crataegolic acid.
A kind of preparation method of the pharmaceutical composition for treating apositia, comprises the following steps：
A. bromisoval Procaine injection, olive oil, honey are well mixed first, obtain mixed liquor；
B. and then by melanterite, crataegolic acid, B B-complex, hawthorn, seaweeds, Isosilybin, isoflavones mixing, Stir, obtain mixture；
C. said mixture, mixed liquor are mixed with bovine bone powder, is placed in baking oven under the conditions of 85-95 DEG C and dries 25- 35min, take out, carry out ultramicro grinding using ball mill, rotating speed be 200-350r/min, ratio of grinding media to material be 5-7 under conditions of, powder Broken 10-20min, obtains ultra micro mixed-powder；
D. pelletize：Take mixed liquor to be placed in the efficient asymmetric mixer of V-type, be subsequently adding pilocarpinum and ultra micro mixing Powder, mixes 2-3 time, each 3-5min under conditions of speed of agitator is 30-50r/min, after being well mixed, crosses 20-50 mesh Sieve series grain, obtains softwood；
E. compressing tablet：Methylephedrine is added in above-mentioned softwood, tabletting machine is used after being well mixed, and gone out using radiation Get product after bacterium.
As further scheme of the invention：Step c. mixes said mixture, mixed liquor with bovine bone powder, puts 30min is dried under the conditions of 88 DEG C in baking oven, is taken out, using ball mill ultramicro grinding is carried out, be 300r/min, ball in rotating speed Material is than under conditions of 6, to crush 15min, obtaining ultra micro mixed-powder.
As further scheme of the invention：The step d. granulation：Take mixed liquor and be placed in V-type efficiently asymmetric mixing In machine, pilocarpinum and ultra micro mixed-powder are subsequently adding, the mixing 3 times under conditions of speed of agitator is 45r/min, every time 5min, after being well mixed, crosses the granulation of 30 mesh sieves, obtains softwood.
Compared with prior art, the invention has the beneficial effects as follows：
The pharmaceutical composition of the treatment apositia by raw material compounding play synergy, with strengthening the spleen and replenishing qi, excreting dampness and Stomach, the curative effect of beneficial gas nourishing, energy effectively treatment apositia, and Small side effects, will not produce complication, and drug withdrawal is not recurred, used Effect preferably, protects the health of people.
Specific embodiment
The technical scheme of this patent is described in more detail with reference to specific embodiment.
Embodiment 1
A kind of pharmaceutical composition for treating apositia, including the raw material of following parts by weight：5 parts of melanterite, pilocarpinum 1 Part, 0.1 part of B B-complex, 1 part of hawthorn, 5 parts of bromisoval Procaine injection, 1 part of seaweeds, 2 parts of bovine bone powder, different fine grinding 1 part of Ji guest, 2 parts of honey, 2 parts of isoflavones, 3 parts of olive oil, 2 parts of methylephedrine, 0.5 part of crataegolic acid.
A kind of preparation method of the pharmaceutical composition for treating apositia, comprises the following steps：
A. bromisoval Procaine injection, olive oil, honey are well mixed first, obtain mixed liquor；
B. and then by melanterite, crataegolic acid, B B-complex, hawthorn, seaweeds, Isosilybin, isoflavones mixing, Stir, obtain mixture；
C. said mixture, mixed liquor are mixed with bovine bone powder, is placed in baking oven and dries 25min under the conditions of 85 DEG C, taken Go out, using ball mill ultramicro grinding carried out, rotating speed be 200r/min, ratio of grinding media to material be 5 under conditions of, crush 10min, surpassed Microring array powder；
D. pelletize：Take mixed liquor to be placed in the efficient asymmetric mixer of V-type, be subsequently adding pilocarpinum and ultra micro mixing Powder, mixes 2 times, each 3min under conditions of speed of agitator is 30r/min, after being well mixed, crosses the granulation of 20 mesh sieves, obtains Softwood；
E. compressing tablet：Methylephedrine is added in above-mentioned softwood, tabletting machine is used after being well mixed, and gone out using radiation Get product after bacterium.
Embodiment 2
A kind of pharmaceutical composition for treating apositia, including the raw material of following parts by weight：10 parts of melanterite, pilocarpinum 5 parts, 1 part of B B-complex, 3 parts of hawthorn, 20 parts of bromisoval Procaine injection, 5 parts of seaweeds, 8 parts of bovine bone powder, different fine grinding 3 parts of Ji guest, 5 parts of honey, 5 parts of isoflavones, 10 parts of olive oil, 5 parts of methylephedrine, 1 part of crataegolic acid.
A kind of preparation method of the pharmaceutical composition for treating apositia, comprises the following steps：
A. bromisoval Procaine injection, olive oil, honey are well mixed first, obtain mixed liquor；
B. and then by melanterite, crataegolic acid, B B-complex, hawthorn, seaweeds, Isosilybin, isoflavones mixing, Stir, obtain mixture；
C. said mixture, mixed liquor are mixed with bovine bone powder, is placed in baking oven and dries 35min under the conditions of 95 DEG C, taken Go out, using ball mill ultramicro grinding carried out, rotating speed be 350r/min, ratio of grinding media to material be 7 under conditions of, crush 20min, surpassed Microring array powder；
D. pelletize：Take mixed liquor to be placed in the efficient asymmetric mixer of V-type, be subsequently adding pilocarpinum and ultra micro mixing Powder, mixes 3 times, each 5min under conditions of speed of agitator is 50r/min, after being well mixed, crosses the granulation of 50 mesh sieves, obtains Softwood；
E. compressing tablet：Methylephedrine is added in above-mentioned softwood, tabletting machine is used after being well mixed, and gone out using radiation Get product after bacterium.
Embodiment 3
A kind of pharmaceutical composition for treating apositia, including the raw material of following parts by weight：8 parts of melanterite, pilocarpinum 3 It is part, 0.6 part of B B-complex, 1.8 parts of hawthorn, 15 parts of bromisoval Procaine injection, 2 parts of seaweeds, 4 parts of bovine bone powder, different 1.7 parts of legalon, 3.5 parts of honey, 4 parts of isoflavones, 7 parts of olive oil, 3.5 parts of methylephedrine, 0.7 part of crataegolic acid.
A kind of preparation method of the pharmaceutical composition for treating apositia, comprises the following steps：
A. bromisoval Procaine injection, olive oil, honey are well mixed first, obtain mixed liquor；
B. and then by melanterite, crataegolic acid, B B-complex, hawthorn, seaweeds, Isosilybin, isoflavones mixing, Stir, obtain mixture；
C. said mixture, mixed liquor are mixed with bovine bone powder, is placed in baking oven and dries 30min under the conditions of 88 DEG C, taken Go out, using ball mill ultramicro grinding carried out, rotating speed be 300r/min, ratio of grinding media to material be 6 under conditions of, crush 15min, surpassed Microring array powder；
D. pelletize：Take mixed liquor to be placed in the efficient asymmetric mixer of V-type, be subsequently adding pilocarpinum and ultra micro mixing Powder, mixes 3 times, each 5min under conditions of speed of agitator is 45r/min, after being well mixed, crosses the granulation of 30 mesh sieves, obtains Softwood；
E. compressing tablet：Methylephedrine is added in above-mentioned softwood, tabletting machine is used after being well mixed, and gone out using radiation Get product after bacterium.
Experimental example
400 apositia patients are chosen, is divided into 1 group for the treatment of, 2 groups for the treatment of, treated 3 groups and control group, each 100.Treatment 1 In group, man 55, female 45.Treat in 2 groups, man 50,50.Treat in 3 groups, man 52, female 48.In control group, man 49, female 51.Each group compares that there was no significant difference in age, sex, the course of disease, with comparativity (P>0.05).
Diagnostic criteria
(1) cardinal symptom：Apocleisis or the food refusal course of disease excluded the sheet caused by other acute and chronic diseases more than 1 month Disease.(2) minor symptom：Sallow complexion, spirit is slightly poor, and muscle is soft or body is become thin, shapeless or band indigestion food of defecating, Easily perspire, tongue nature is light, tongue is thin white, and arteries and veins is powerless.It is all to possess above primary symptom and the i.e. diagnosable apocleisis of more than three persons of minor symptom Disease.
Treat pharmaceutical composition prepared by 1 group of oral embodiment 1 to be treated, treat prepared by 2 groups of oral embodiments 2 Pharmaceutical composition treats pharmaceutical composition prepared by 3 groups of oral embodiments 3 to be treated, twice daily, often being treated Secondary oral 3g, continuous treatment 7 days.
The oral polyzyme tablets of control group (contains 300 milligrams of pancreatin, 13 milligrams of pepsin per piece), twice daily, oral every time Two panels, continuous treatment 7 days.
Criterion of therapeutical effect
It is effective：Appetite is significantly increased, and appetite increases up to normal health youngster, and simultaneous phenomenon disappears, without multiple in 6 months after treatment Send out.
Effectively：Appetite is substantially recovered, and appetite increases and returns to the 3/4 of normal level, simultaneous phenomenon improvement, 6 after treatment Without recurrence in individual month.
It is invalid：Not substantially, simultaneous phenomenon can have improvement for appetite, appetite change.
The results are shown in Table 1：
The treatment group of table 1 and the treatment results of control group
Project Number of cases/example Effective/example Effectively/example Invalid/example Efficient/%
Treat 1 group 100 76 100 0 100
Treat 2 groups 100 78 99 1 99
Treat 3 groups 100 89 100 0 100
Control group 100 19 79 21 79
It can be seen from Table 1 that, the pharmaceutical composition of the present invention can be with effectively treatment apositia, and non-relapse after healing, Embodiment 1-3 prepare pharmaceutical composition average effectiveness level be higher than 99%, be it is a kind of can be with the medicine of effectively treatment apositia.Should The pharmaceutical composition for the treatment of apositia plays synergy by raw material compounding, nourishes with strengthening the spleen and replenishing qi, excreting dampness and stomach, beneficial gas Curative effect, can effectively treatment apositia, and Small side effects will not produce complication, and drug withdrawal is not recurred, and using effect preferably, is protected The health of people is protected.
The better embodiment of this patent is explained in detail above, but this patent is not limited to above-mentioned embodiment party Formula, in the ken that one skilled in the relevant art possesses, can be with the premise of without departing from this patent objective Make a variety of changes.

Claims (6)

1. a kind of pharmaceutical composition for treating apositia, it is characterised in that including the raw material of following parts by weight：Melanterite 5-10 Part, pilocarpinum 1-5 parts, B B-complex 0.1-1 parts, hawthorn 1-3 parts, bromisoval Procaine injection 5-20 parts, sea Algae element 1-5 parts, bovine bone powder 2-8 parts, Isosilybin 1-3 parts, honey 2-5 parts, isoflavones 2-5 parts, olive oil 3-10 parts, Methylephedrine 2-5 parts, crataegolic acid 0.5-1 parts.
2. it is according to claim 1 treatment apositia pharmaceutical composition, it is characterised in that including following parts by weight Raw material：Melanterite 6-9 parts, pilocarpinum 2-3.5 parts, B B-complex 0.4-0.8 parts, hawthorn 1.5-2 parts, bromisoval Proca Because of parenteral solution 10-18 parts, seaweeds 1.5-3.5 parts, bovine bone powder 3-5 parts, Isosilybin 1.5-2 parts, honey 3-4 parts, soybean Isoflavones 3-4.5 parts, olive oil 5-8 parts, methylephedrine 3-4 parts, crataegolic acid 0.6-0.8 parts.
3. it is according to claim 1 treatment apositia pharmaceutical composition, it is characterised in that including following parts by weight Raw material：8 parts of melanterite, 3 parts of pilocarpinum, 0.6 part of B B-complex, 1.8 parts of hawthorn, bromisoval Procaine injection 15 Part, 2 parts of seaweeds, 4 parts of bovine bone powder, 1.7 parts of Isosilybin, 3.5 parts of honey, 4 parts of isoflavones, 7 parts of olive oil, methyl 3.5 parts of ephedrine, 0.7 part of crataegolic acid.
4. a kind of preparation method of the pharmaceutical composition of the treatment apositia as described in claim 1-3 is arbitrary, it is characterised in that Comprise the following steps：
A. bromisoval Procaine injection, olive oil, honey are well mixed first, obtain mixed liquor；
B. and then by melanterite, crataegolic acid, B B-complex, hawthorn, seaweeds, Isosilybin, isoflavones mixing, stir Uniformly, mixture is obtained；
C. said mixture, mixed liquor are mixed with bovine bone powder, are placed in baking oven under the conditions of 85-95 DEG C and dry 25-35min, Take out, carry out ultramicro grinding using ball mill, rotating speed be 200-350r/min, ratio of grinding media to material be 5-7 under conditions of, crush 10- 20min, obtains ultra micro mixed-powder；
D. pelletize：Take mixed liquor to be placed in the efficient asymmetric mixer of V-type, be subsequently adding pilocarpinum and ultra micro mixed powder End, mixes 2-3 time, each 3-5min under conditions of speed of agitator is 30-50r/min, after being well mixed, crosses 20-50 mesh sieves Granulation, obtains softwood；
E. compressing tablet：Add methylephedrine in above-mentioned softwood, after being well mixed use tabletting machine, and using radiation sterilization after Get product.
5. it is according to claim 1 treatment apositia pharmaceutical composition preparation method, it is characterised in that the step C. said mixture, mixed liquor are mixed with bovine bone powder, is placed in baking oven and dries 30min under the conditions of 88 DEG C, taken out, using ball Grinding machine carries out ultramicro grinding, rotating speed be 300r/min, ratio of grinding media to material be 6 under conditions of, crush 15min, obtain ultra micro mixed powder End.
6. it is according to claim 1 treatment apositia pharmaceutical composition preparation method, it is characterised in that the step D. pelletize：Take mixed liquor to be placed in the efficient asymmetric mixer of V-type, be subsequently adding pilocarpinum and ultra micro mixed-powder, Speed of agitator is to mix 3 times under conditions of 45r/min, each 5min, after being well mixed, crosses the granulation of 30 mesh sieves, obtains softwood.
CN201611252700.5A 2016-12-30 2016-12-30 Pharmaceutical composition for treating anorexia Pending CN106619876A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611252700.5A CN106619876A (en) 2016-12-30 2016-12-30 Pharmaceutical composition for treating anorexia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611252700.5A CN106619876A (en) 2016-12-30 2016-12-30 Pharmaceutical composition for treating anorexia

Publications (1)

Publication Number Publication Date
CN106619876A true CN106619876A (en) 2017-05-10

Family

ID=58836881

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611252700.5A Pending CN106619876A (en) 2016-12-30 2016-12-30 Pharmaceutical composition for treating anorexia

Country Status (1)

Country Link
CN (1) CN106619876A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021214175A1 (en) 2020-04-21 2021-10-28 Université Catholique de Louvain Alpha-2 adrenergic receptor agonists for the prevention and/or the treatment of spleen disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021214175A1 (en) 2020-04-21 2021-10-28 Université Catholique de Louvain Alpha-2 adrenergic receptor agonists for the prevention and/or the treatment of spleen disorders

Similar Documents

Publication Publication Date Title
KR20150105714A (en) composition for health functional food improving joint health
CN104906326B (en) A kind of gastrin magnesium granules and preparation method thereof
CN106619876A (en) Pharmaceutical composition for treating anorexia
CN103784905A (en) Traditional Chinese medicine powder for treating swine edema and preparation method thereof
CN108079225A (en) A kind of stomach nourishing health food making method and its application
CN101837019A (en) American cockroach medicinal composition for curing oral ulcers and preparation method thereof
CN105963688A (en) Powder for curing intestinal diseases of piglet and enhancing immunity and preparation method thereof
CN109999117A (en) Prevent and treat enteritis, bacillary dysentery, dysentery, intractable diarrhea Chinese medicine composition
CN101837022A (en) American cockroach medicinal composition for curing gastritis and peptic ulcers and preparation method thereof
CN106491699A (en) One kind treats dyspeptic Western medicine compound and preparation method thereof
CN101450074B (en) Composition capable of greatly improving gastrointestinal tract function and preventing and treating astriction
CN106361796A (en) Western medicine composition for treating anorexia
CN106924539A (en) A kind of Chinese medicine preparation for treating peptic ulcer, gastritis and reflux esophagitis and its preparation method and application
CN106389869A (en) Immunity-enhancing health product
CN102552743A (en) Medicinal composition for treating diabetes and preparation method thereof
CN105194026A (en) Traditional Chinese medicine composition used for treating non-infectious diarrhea of cage rearing chicken as well as preparation method and application thereof
CN110755533A (en) Traditional Chinese medicine solution for treating skin diseases and preparation method and application thereof
CN109078089A (en) A kind of anti-aging, the Chinese medicine composition and its preparation for preventing and treating osteoporosis
CN100512861C (en) Medicine for preventing and treating diarrhea of livestock and poultry
CN117959372B (en) Therapeutic pharmaceutical composition for peptic gastric ulcer and preparation method thereof
KR102439636B1 (en) Composition for alleviating muscle tics and depression and manufacturing method thereof
US20040022880A1 (en) Extracts of mixed arctium lappa L., carrot and whole radish for treating hypertension, constipation and detoxification
CN106728071A (en) It is a kind of to treat medicine of gastric ulcer and preparation method thereof
CN102961732B (en) The composition and method of making the same for the treatment of rabbit enteritis
CN108785649B (en) Composition for controlling weight of pressure type obesity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170510